GCAN · Greater Cannabis Company, Inc.
$0.34
+0.07 (+24.10%)
At close · Jul 21
Going-concern doubt
— flagged May 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We have therefore concluded there is substantial doubt about our ability to continue as a going concern through March 2027.”View the 10-Q filed May 13, 2026
Market Cap
$316,741
Shares
944,935
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$12.63K
-73.7%
FY2021
Net Income
-$331.61K
-85.2%
FY2025
Gross Margin
-0.2%
-0.1pp
FY2021
Operating Margin
-2716.91%
-2104pp
FY2021
Diluted EPS
$0.00
FY2025
Operating Cash Flow
-$60.15K
+45.1%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $12.63K | $48.04K | $7120 | $95.38K | $209 | — | — | |
| — | — | — | — | — | $12.66K | $48.09K | $3125 | — | $109 | — | — | |
| — | — | — | — | — | -$25 | -$46 | $3995 | $86.9K | $100 | — | — | |
| — | — | — | — | — | -0.2% | -0.1% | 56.11% | 91.11% | 47.85% | — | — | |
| — | $417 | $5000 | $5000 | — | — | — | $20K | $10.25K | — | — | — | |
| $172.85K | $183.01K | $156.28K | $175.36K | $177.04K | $343.12K | $294.41K | $529.32K | $286.29K | $622.66K | $100K | — | |
| -$172.85K | -$183.01K | -$156.28K | -$175.36K | -$177.04K | -$343.15K | -$294.46K | -$525.32K | -$190.92K | -$622.56K | -$100K | — | |
| — | — | — | — | — | -2716.91% | -612.89% | -7378.13% | -200.18% | -297873.68% | — | — | |
| $12.72K | — | — | — | — | — | — | — | — | -$4551 | -$3000 | — | |
| — | -$148.61K | -$22.77K | -$13.04K | -$183.23K | -$259.08K | -$656.71K | -$1.12M | -$648.15K | $184.65K | $3000 | — | |
| -$261.48K | -$331.61K | -$179.04K | -$188.4K | -$360.27K | -$602.23K | -$951.17K | -$1.65M | -$839.07K | — | — | — | |
| -$261.48K | -$331.61K | -$179.04K | -$188.4K | -$360.27K | -$602.23K | -$951.17K | -$1.65M | -$839.07K | -$807.21K | -$103K | -$3206 | |
| — | — | — | — | — | -4768.22% | -1979.79% | -23154.42% | -879.76% | -386224.4% | — | — | |
| USD/shares | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — |
| USD/shares | — | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — | — | — | — | — |
| shares | — | 824.98K | 536.62K | 503.44K | 391.85K | 326.34K | 96.89K | 23.32K | 19.98K | 18.65K | 17.94K | — |
| shares | — | 824.98K | 536.62K | 503.44K | 391.85K | 326.34K | 96.89K | 23.32K | 19.98K | 18.65K | 17.94K | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.27×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.76×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 20.49×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2021 | FY2020 |
|---|---|---|
| Product | $12,630 | $48,044 |